

## Novartis to acquire Xiidra in a \$5.3B deal

10 May 2019 | News

Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye byinhibiting inflammation caused by the disease



Novartis announced that it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra® (lifitegrast ophthalmic solution) 5% worldwide.

Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction would bolster the Novartis front-of-the-eye portfolio and ophthalmic leadership.

Closing of the transaction is expected in second half of 2019, subject to customary closing conditions including regulatory approvals. On closing, Novartis plans a smooth transition of operations and integration of Xiidra into its pharmaceuticals portfolio.

Dry eye is a common inflammatory disease that, left untreated, can become extremely painful and lead to permanent damage to the cornea and vision. This damage manifests in the form of signs that can be objectively measured by eye care professionals through various clinical tests (such as corneal staining), and symptoms (such as pain and discomfort).

Xiidra, with its anti-inflammatory mechanism of action, is the first dry eye treatment approved to treat both the signs of eye damage and the physical symptoms experienced by patients. Additional benefits of Xiidra, exhibited in phase III studies, include a timely onset of action and well-tolerated safety profile.

Paul Hudson, CEO Novartis Pharmaceuticals said, "Xiidra, with its unique dual benefits, is an example of the type of innovative advances we invest in for the benefit of patients. We look forward to leveraging our well-established commercial infrastructure to bring this medicine to more patients."

In addition to powering Novartis' ability to serve more patients suffering from eye disease, the additional commercial experience established with Xiidra is expected to better position the company for front-of-the-eye pipeline products currently in development.

nt payment with potenti oproximately 400 emplo	ial milestone payments o yees associated with the	f up to USD 1.9 billion product.	n. As part of
	nt payment with potent oproximately 400 emplo	nt payment with potential milestone payments of proximately 400 employees associated with the	nt payment with potential milestone payments of up to USD 1.9 billion proximately 400 employees associated with the product.